Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IO102/IO103 and Nivolumab-relatlimab in Untreated, Unresectable Stage III/IV Melanoma
NCT05912244Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2023
- Primary completion
- Jun 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PD-L1/IDO peptide vaccine in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2023; status: active, not recruiting.
02
Drugs
PD-L1/IDO peptide vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05912244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912244.